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ABSTRACT
Background and Aims Although clear beneﬁts are associated with reducing smoking, there is increasing pressure on
public health providers to justify investment in tobacco control measures. Decision-makers need tools to assess the Return
on Investment (ROI)/cost-effectiveness of programmes. The EQUIPT project adapted an ROI tool for England to four
European countries (Germany, the Netherlands, Spain and Hungary). EQUIPTMOD, the economic model at the core of
the ROI tool, is designed to assess the efﬁciency of packages of smoking cessation interventions. The objective of this paper
is to describe themethods for EQUIPTMOD and identify key outcomes associatedwith continued and cessation of smoking.
Methods EQUIPTMOD uses a Markov model to estimate life-time costs, quality-adjusted life years (QALYs) and life years
associated with a current and former smoker. It uses population data on smoking prevalence, disease prevalence, mortality
and the impact of smoking combined with associated costs and utility effects of disease. To illustrate the tool’s potential,
costs, QALYs and life expectancy were estimated for the average current smoker for ﬁve countries based on the
assumptions that they continue and that they cease smoking over the next 12 months. Costs and effects were discounted
at country-speciﬁc rates. Results For illustration, over a life-time horizon, not quitting smoking within the next
12 months in England will reduce life expectancy by 0.66, reduce QALYs by 1.09 and result in £4961 higher
disease-related health care costs than if the smoker ceased smoking in the next 12months. For all age–sex categories, costs
were lower and QALYs higher for those who quit smoking in the 12 months than those who continued.
Conclusions EQUIPTMOD facilitates assessment of the cost effectiveness of smoking cessation strategies. The
demonstrated results indicate large potential beneﬁts from smoking cessation at both an individual and population level.
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INTRODUCTION
Smoking has a signiﬁcant negative health impact, with
more than 1 billion dollars spent every year on treating
smoking-attributable diseaseswithin Europe [1]. It is linked
to many health conditions, including coronary heart
disease, stroke, respiratory illnesses and certain cancers [2].
Moreover, it is the largest avoidable risk factor, responsible
for more than 700 000 European deaths each year [3].
The large health and economic impact of smoking has
led to recommendations to focus on reducing smoking
rates and increasing measures to decrease the impact of
second-hand smoke. Although there are clear beneﬁts
to public health measures to reduce smoking, in the
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current era of scarce resources there is also increasing
pressure on public health providers to justify the invest-
ment in tobacco control measures. Decision-makers at
regional and national levels need tools to help assess the
return on investment/cost–effectiveness of programmes
and to produce easily interpreted outputs, thereby
allowing clear presentation of the ﬁndings as justiﬁcation
for implementation of smoking cessation programme
proposals.
Return on Investment (ROI) forecasting models have
been used in the past to help employers justify invest-
ment in health promotion programmes within a number
of US companies [4]. A recent example of the implemen-
tation of a novel ROI tool designed for use by local
public health decision-makers is the NICE (The National
Institute for Health and Care Excellence) smoking cessa-
tion ROI tool developed for England, whose aim was to
assist local decision-makers with calculating the balance
of the investment required for implementation of
smoking cessation programmes and the health and eco-
nomic beneﬁts of stopping smoking [5]. The European
Study on Quantifying Utility of Investment in Protection
from Tobacco (EQUIPT) project has been funded to build
on the success of the NICE ROI [6]. EQUIPT aimed to
adapt the existing ROI tool for four additional core
European countries (Germany, the Netherlands, Spain
and Hungary) in addition to England within its initial
phase, and subsequently explore the potential for these
models to be adapted to meet the needs of additional
European countries.
The EQUIPT ROI tool was designed to address the deci-
sion problem relating to identifying what is the optimal
package of smoking cessation interventions for commis-
sioners at all levels of smoking cessation interventions. At
the core of the EQUIPT ROI tool is an economic model,
EQUIPTMOD, which forecasts the short- and long-term
outcomes for smokers who cease smoking within the next
calendar year or continue smoking. These outcomes can
then be used to forecast the impact of a variety of smoking
cessation interventions. The objective of this paper is to
describe the methods for EQUIPTMOD and to apply the
model to identify the key outcomes associated with both
continued and cessation of smoking within the ﬁve initial
partner countries.
METHODS
Decision problem
EQUIPTMOD is designed to facilitate the determination of
an optimal package of smoking cessation interventions.
Thus, the speciﬁc decision problem relates to identifying
those interventions which can be considered cost-effective.
EQUIPTMOD allows the determination of a range of
relevant outcomes which are a factor of the estimated costs
and outcomes associated with continuing and stopping
smoking. In this paper, we will describe the methods for
EQUIPTMOD and illustrate the potential of the model by
estimating the life-time costs, quality-adjusted life years
(QALYs) and life years associated with a current smoker
and former smoker.
Population
The population of interest is the current smoking popula-
tion within the ﬁve core European countries. The popula-
tion is stratiﬁed by age (by individual birth year) and sex
(male, female), with estimates weighted by the actual
number of smokers in each strata.
Comparators
Decision-makers can consider a variety of potential pack-
ages of smoking cessation interventions at both the
individual and population levels. Three packages can be
considered at any one time: default data relating to the
currently implemented tobacco control intervention
package within the selected country or region, a minimal
investment package which relates to no continued funding
of interventions and a user-deﬁned package. For the latter
package, users can customize the investment in existing
smoking cessation interventions and can incorporate
new previously unfunded interventions into the package.
Within the interface, users can change default parameters
such as discount rates and threshold values for a QALY.
Once the packages have been developed, users can
overview the different potential metrics for each
permissible time horizon.
Outcomes
The ﬂexibility of EQUIPTMOD allows the derivation of a
number of metrics for determining the return on invest-
ment from the alternate packages. Metrics include avoid-
able burden of disease (QALYs), beneﬁt–cost ratios, net
beneﬁt analysis and incremental cost-effectiveness ratios
incorporating deaths avoided, life years gained and QALYs
gained. Each of these outcomes are a function of the costs,
life years and QALYs associated with continuing and
stopping smoking and the impact of each package on the
rate of cessation. These metrics were selected on the basis
of previous work carried out by NICE and feedback from
stakeholders [5,7].
In forecasting outcomes such as life years, QALYs and
costs, the model adopts a health-care perspective in which
costs and beneﬁts to the health-care system realized both
by individuals who continue smoking and those who cease
smoking within 1 year are estimated. The model has been
designed to enable customization within the interface to
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provide estimates of costs and outcomes at various
time-points, including 2, 5 and 10 years and a life-time
(until an individual is 100 years of age). The model adopts
country-speciﬁc discounting rates [8–12].
Design of the model
The EQUIPT ROI tool uses a Markov state transition co-
hort model to estimate long-term outcomes [13]. There
are three primary states within the model: current
smoker, former smoker and death (Fig. 1). The cycle
length is 1 year. The Markov model is constructed within
Excel with a user-friendly interface developed through
Visual Basic.
With each 1-year cycle the cohort is subjected to a set of
transition probabilities which allow them to either stay
within their current state or move to one of the other
two states. Death is an absorbing state, meaning that those
who enter this state remain within the state.
The model is replicated through a series of data tables
within Excel for different population cohorts based on
age (16–85; 18–85 years for Germany) and sex. To
obtain population-level estimates, these cohort-level
estimates are weighted by the percentage of the smoking
population falling into each age (by individual year) and
sex cohort [14–19].
To calculate the relevant outcomes for a package of
interventions, two separate models were created to
simulate the health impacts of either quitting or not
quitting smoking during the ﬁrst cycle of the model— i.e.
the cohort of smokers who quit and those who do not quit
are modelled separately, with the results combined by
weighting the outputs of themodels by the country-speciﬁc
population and the package effectiveness and uptake.
Transition probabilities
Within the model, three sets of annual transition probabil-
ities are required:
• Package-speciﬁc probability of quitting smoking in the
ﬁrst cycle (year) based on the uptake and effectiveness
of interventions within the package;
• Age–gender-speciﬁc annual probability of mortality
associated with current smoking and being a former
smoker; and
• Long-term annual probabilities of smoking cessation for
current smokers and relapse for former smokers.
The probability that current smokers will quit during
the ﬁrst cycle is a function of the proportion of the cohort
who will make a quit attempt during the ﬁrst year; the
uptake of smoking cessation interventions in this group;
the probability of a successful quit attempt with each
intervention; and the probability of a successful quit
attempt in those attempting to quit unassisted.
In order to estimate the probability of death by age and
sex and smoking status, the following data were required:
age–sex-speciﬁc probability of death in the general popula-
tion, the age–sex-speciﬁc prevalence of smoking status
(current, former or never smokers) and the relative risk of
death by smoking status. Actuarial life tables and
Figure 1 Schematic of Markov model [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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age–sex-speciﬁc prevalence of smoking were provided by
each of the participating countries [20–29]. The relative
risks of death for former and current smokers versus never
smokers were derived from published data [30].
Long-term cessation and relapse were modelled
through the application of an underlying quit rate which
applies to all age–sex-speciﬁc cohorts after the ﬁrst year.
The underlying quit rate represents a balance of those
who quit smoking eachyear and those who start or relapse
to smoking [31]. For all participating countries this
produces an underlying quit rate of approximately 2% in
the general smoking population, except for within
Hungary, where the rate is 1%.
Prevalence of smoking-related diseases
The Markov model estimates the proportion of the cohort
who are either current smokers, former smokers or dead
within each cycle. Based on available epidemiological data
the model estimates, for each cycle, the prevalence of
smoking-related diseases through assessing smoking-
related population-attributable fractions relating to
current and former smokers.
Four diseases were incorporated, based on the
increased burden associated with smoking behaviours:
lung cancer, coronary heart disease (CHD), chronic
obstructive pulmonary disease (COPD) and stroke
[2,32]. These diseases account for approximately 75%
of smoking-related deaths [32]. To estimate the number
of cases each year of these diseases with and without
smoking cessation during the ﬁrst cycle, the following
data were required: the prevalence of smoking-related
diseases, the prevalence of smoking status (current,
former or never smokers) and the relative effect of
smoking on the prevalence of each disease. Each partner
country provided age–sex-speciﬁc estimates of the ﬁrst
two parameters, while the same data are employed
relating to relative effects [19,23,28,33–44].
Costs
Within the model, costs include both the costs of the
interventions contained within each package and the
health-care costs associated with these diseases. For each
country, the annual health-care costs for an individual
with each of the diseases were estimated based on a
systematic literature review [45–55]. Costs relate to
prevalent cases of disease. Based on the available data,
estimates were derived either by dividing life-time
health-care costs of disease by the estimated life expec-
tancy after developing the disease or by dividing the
estimated annual health-care costs of the disease by the
prevalence of the disease in the given year.
Utility values
To identify sources for utility values for the model, each
country conducted a search of the literature, with poten-
tial sources being evaluated against a predetermined
criteria hierarchy. The criteria included the use of a vali-
dated instrument to evaluate quality of life, values
reﬂective of the population of individuals with the
disease/smoking status (i.e. the severity of disease and
age/sex distribution of the sample from which the values
were derived should be reﬂective of the population at
large with the disease/smoking status), country-speciﬁc
sources and the incorporation of an estimate of the un-
certainty in the reported value. Utility values based on
current smoking status (current or former) were derived
from the Health Survey for England adjusted for relevant
covariates, including disease prevalence [56]. Utility dec-
rements associated with smoking-attributable diseases
were derived from the US Medical Expenditure Panel
Survey [57]. Both sets of utility values were elicited using
the EQ-5D questionnaire, a validated instrument for mea-
suring health-related quality of life, and UK tariffs were
used for calculating utility scores. These two sources
were selected as they met the greatest number of the
criteria against which they were evaluated (i.e. three of
the four requirements).
Intervention-based parameters
For each intervention a decision-maker wishes to include
within themodel, the following datawould be required: rel-
ative effect sizes, costs and uptake rate. Currently, the
EQUIPT ROI tool incorporates such parameters for a vari-
ety of interventions.
Obtaining parameter values
A comprehensive list of all parameters required within the
model was provided to country-speciﬁc modellers in order
to facilitate the gathering of this information (Table 1).
Modellers were required to search both administrative
databases and published literature to source these data,
which were then incorporated within the EQUIPT tool.
The modellers completed this search and provided data to
the principal modeller and the datawere then incorporated
within the current model.
As the model is designed to give results over the entire
smoking population and not the individual age–sex cohorts
and is able to produce both country-level and regional
results, a number of additional input parameters with
respect to population counts and vital statistics were
required for populating the model. These included the
population by age and sex, the prevalence of smokers and
former smokers and the employment rate for smokers, all
at both country and regional levels. Also required were
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country-speciﬁc life tables for calculating mortality and
information regarding inﬂation rates for adjusting
historical costs and currency conversion rates.
Key assumptions
As is the case with all models, a number of assumptions
were required to estimate the economic impact of tobacco
control interventions. These are described below.
The population-based mortality rates are adjusted
using the relative risks of death in smokers and former
smokers, which are derived from the literature [30].
Although the reference is dated and absolute mortality
may have changed, the assumption that the relative
effect was likely to be maintained and the choice of study
was justiﬁed based on the prospective nature of the study,
the sample size (n = 34439) and the years of follow-up
(40 years).
The current model does not adjust explicitly for the
time since quitting, due to the absence of distributional
data regarding time since quitting and duration of smoking
and the risk of smoking-related disease and mortality.
Rather, an average risk of smoking-attributable disease
and mortality is applied to former smokers. As this is a
cohort, rather than an individual patient simulation
model, the impact of this assumption may be limited.
Given the lack of data to support an alternative
assumption, the prevalence of each disease is assumed
to be independent of the prevalence of other diseases.
Also, the model assumes that in the case of multiple
diseases, the disutility associated with the disease with
the greatest disutility is applied. This is a conservative
approach, in that it provides a lesser estimate of the
QALY gains from smoking cessation than either a
multiplicative or additive approach.
For all diseases, in people aged below 35 years the risk
of smoking-attributable disease was assumed to be equal
across smoking groups. This was deemed to be the most
appropriate assumption, given that data regarding the
differential rate of all diseases by smoking status were not
available for this age group. This assumption is both
conservative and, given the very low prevalence of disease
in this group, unlikely to have a signiﬁcant impact on the
results.
The underlying quit rate, which applies to all cohorts
after the ﬁrst year, represents a balance of those who
quit smoking each year and those who start or relapse
to smoking. This assumption is supported by a meta-
analysis which showed that there was no difference in
relapse rates after 12 months, regardless of whether
the patients used an intervention to quit smoking or
no intervention [58].
Handling uncertainty
Within EQUIPTMOD, the effect of parameter uncertainty
on the calculated outcomes can be assessed through
probabilistic sensitivity analyses involving Monte Carlo
simulation (MCS) [59]. For the MCS, probability
distributions related to natural history parameters, relative
risks and odds ratios, costs and utilities are incorporated
into the model.
Analysis adopts standard methods for deﬁning uncer-
tainty around parameters [59]. Transition probabilities
are characterized by beta distributions and relative risks
and odds ratios are characterized by log-normal distribu-
tions. Utility values by smoking status are characterized
by beta distributions, while utility decrements associated
Table 1 Data elements required to derive estimates of life-time
costs and quality adjusted life years (QALYs).
Parameter Source
Discount rate 8–12
Population estimates by age and gender 14–19
Annual probability of death by age and sex 20–24
Prevalence of smoking by age and gender 25–29
Never smoker
Former smoker
Current smoker
Relative risk of death by smoking status 30
Background quit rate 31
Relative risk of smoking attributable disease
by age, sex and smoking status
2,32
Lung cancer
CHD
Stroke
COPD
Prevalence of smoking attributable disease by
age and sex
19, 23,33–44
Lung cancer
CHD
Stroke
COPD
Costs of smoking attributable disease 45–55
Lung cancer
CHD
COPD
Stroke
Utility values by smoking status 56
Smoker
Former smoker
Never smoker
Utility values associated with smoking
attributable disease
57
Lung cancer
CHD
COPD
Stroke
CHD = coronary heart disease; COPD = chronic obstructive pulmonary
disorder.
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with smoking-related disease are characterized by normal
distributions. Costs are characterized by gamma distribu-
tions. Both intervention costs and population level data
are assumed ﬁxed.
As a default, 1000 replications are conducted; i.e. a set
of 1000 outcome estimates are obtained. The results are
displayed by a scatterplot of costs versus QALYs and by
cost-effectiveness acceptability curves (CEACs) that present
graphically the probability of being cost-effective as a func-
tion of decision-makers’willingness to pay for a QALY [59].
Analysis
EQUIPTMOD allows calculation of the costs, QALYs and life
expectancy for a population of current smokers who quit
smoking within the ﬁrst cycle of the model and for a popu-
lation of current smokers who do not quit smoking.
For illustration within this paper, the average costs,
QALYs and life expectancy are presented as estimated for
the smoking population in England, Germany, Hungary,
the Netherlands and Spain. Discounted results are pre-
sented using country-speciﬁc discount rates for a life-time
horizon. In addition, the discounted costs and QALYS over
a life-time horizon for England are presented by each age–
sex strata and the discounted and undiscounted costs,
QALYs and life years are presented for alternate time
horizons for England.
Finally, illustrative examples of how these ﬁgures can be
used are provided with respect to three speciﬁc forms of
interventions for England—a population-level intervention
designed to increase the proportion of individuals who will
make a quit attempt during the next 12 months; a novel
individual-based intervention designed to increase the quit
rate in smokers making a quit attempt; and a population-
Table 2 Estimates of average costs, life years (LYs) and quality-adjusted life years (QALYs) for life-time horizons bywhether individual stops
smoking during the ﬁrst cycle.
England Netherlands Germany Spain Hungary
If individual quits in the next 12 months Health-care costs £9602 €12991 €11838 €20044 €10775
QALYs 15.86 16.18 14.81 16.14 14.40
LYs 19.11 19.26 17.98 19.40 17.28
If individual does not quit in the next 12 months Health-care costs £14 563 €20045 €19138 €37742 €19412
QALYs 14.77 15.14 13.27 14.95 12.95
LYs 18.45 18.26 16.75 18.78 16.28
All ﬁgures are discounted. Costs are presented in 2016 £ or €s.
Table 3 Estimate of average life years, quality adjusted life years (QALYs) and costs by alternative time horizons for England.
Discounted Undiscounted
Individuals who
quit smoking in
the 1st cycle
Individuals who do not
quit smoking in the
1st cycle
Difference between
quitters versus
non-quitters
Individuals who quit
smoking in the
1st cycle
Individuals who do not
quit smoking in the
1st cycle
Difference between
quitters versus
non-quitters
Average costs
2 years £566 £1087 –£521 £576 £1106 –£530
5 years £1409 £2635 –£1226 £1510 £2822 –£1312
10 years £2764 £4966 –£2202 £3236 £5786 –£2550
Life-time £9.602 £14 563 –£4961 £23 486 £32 711 –£9225
Life years
2 years 1.94 1.94 0.00 1.97 1.97 0.00
5 years 4.56 4.53 0.03 4.87 4.84 0.03
10 years 8.20 8.10 0.10 9.51 9.38 0.13
Life-time 19.11 18.45 0.66 36.50 34.77 1.73
QALYs
2 years 1.64 1.57 0.07 1.67 1.60 0.07
5 years 3.85 3.67 0.18 4.11 3.92 0.19
10 years 6.91 6.56 0.35 8.00 7.59 0.41
Life-time 15.86 14.77 1.09 29.91 27.54 2.37
Figures are obtained by weighting estimates for each age–sex cohort for England by the proportion of the population in the cohort.
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level intervention designed to increase the uptake of a
cessation intervention in smokers willing to make a quit at-
tempt. These analyses are conducted in the form of a cost–
utility analysis.
RESULTS
Estimated costs, life years and QALYs
Table 2 demonstrates the differences in life-time outcomes
between individuals who quit smoking during the ﬁrst 12
months compared to those who do not. Over the life-time
horizon, quitting smoking during the next 12months leads
to an increase in QALYs of 1.09 (discounted), an increase
in life expectancy of 0.66 (discounted) and a reduction in
health-care costs of £4961 (discounted). The magnitude
of differences varied by countries, although the general
trend in ﬁndings was maintained.
Table 3 provides data for England based on alternative
time horizons and by whether or not results are subject
to discounting. There are no differences in life expectancy,
either discounted or undiscounted, at 2 years, but by
5 years differences are observable with the difference over
a life-time horizon being 0.66 years (discounted) and
1.73 years (undiscounted). Differences in QALYs are ob-
servable at 2 years due to the improved utility value for for-
mer smokers compared to current smokers with a
difference of 0.07 QALYs, both discounted and
undiscounted. Over the life-time horizon the QALY gains
from quitting smoking are 1.09 QALYs (discounted) and
2.37 QALYs (undiscounted). For costs, differences are also
apparent by 2 years. The costs for individuals who quit
smoking during the ﬁrst 12 months compared to those
who do not were £519 lower (discounted) and £530
(undiscounted). Over the life-time horizon the cost
difference rose to £4961 (discounted) and £9225
(undiscounted).
The absolute life-time costs and QALYs by age and gen-
der and smoking status for England vary, but the following
ﬁndings were consistent (Fig. 2). For each age–sex cate-
gory, costs were lower andQALYs higher for those who quit
smoking during the ﬁrst 12 months than those who did
not. Life-time QALYs tended to be higher for females than
males within each smoking category. However, QALYs for
males who quit smoking were higher than for females
who did not quit smoking.
Illustrative examples
For all the illustrative analyses, the following assump-
tions were made. The analyses were conducted for a
smoking population of 2000. Analysis was conducted
for a population corresponding to the current smoking
population in England in terms of the age–sex break-
down and life-time costs and QALYs. The proportion of
smokers in the population who will make a quit attempt
without any interventions will be 20%, and the success
rate of an unaided quit attempt (i.e. without interven-
tions aimed to increase the success rate of a quit
attempt) is 5%.
For the ﬁrst illustrative example, we will assume that
there is a population-level intervention that will lead to a
relative increase in the proportion of smokers who will
make a quit attempt of 25%. The population-level interven-
tion will cost £40000, or £20 per smoker. Based on the es-
timated costs and QALYs in Table 2, the costs and QALYs
associated with the two alternatives, the status quo and
the addition of the population-level intervention, can be es-
timated (Table 4). The incremental cost per QALY gained
for the addition of the population level intervention is
£2788, suggesting that the intervention is cost-effective.
For the second illustrative example, we will assume that
there is a novel individual-level intervention available for
smokers making a quit attempt. The relative risk of quitting
with the new intervention compared to an unaided quit
attempt is 1.25, and the intervention will cost £225 per
attempt. It is assumed that 20% of smokers making a quit
attempt will utilize the new intervention. The incremental
cost per QALY gained for the addition of the novel
individual level intervention is £11962, suggesting that
the intervention is cost-effective (Table 3).
Figure 2 Life-time costs and quality-adjusted life years (QALYs) by
whether or not individual stops smoking during the ﬁrst cycle (England)
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For the third illustrative example, we will assume that
there will be population-level intervention to increase up-
take of the novel individual-level intervention described
above. If the population-level intervention is adopted, the
proportion of smokers making a quit attempt who will
use the novel individual-level intervention will double.
The population-level intervention will cost £50000. The
incremental cost per QALY gained for the addition of the
population-level intervention compared to the novel
individual-level intervention is £57834, suggesting that
the intervention is not cost-effective (Table 3).
DISCUSSION
In this paper we provide the background, methodology,
limitations and initial results relating to EQUIPTMOD: the
Markov model designed to facilitate the assessment of the
cost-effectiveness of alternative strategies to increase the
rates of smoking cessation within participating countries.
When designing studies to be transferable across jurisdic-
tions, it is necessary to harmonize both the study/model
design and data collection [60]. The design of EQUIPTMOD
facilitates such decisions not only in the countries
Table 4 Results of illustrative examples.
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participating in the ﬁrst wave, as highlighted in this paper,
but will allow countries with fewer analytical resources to
adapt the model to provide pertinent information for their
context.
EQUIPT is a rare multi-disciplinary study which allows
assessment of the transferability of economic evidence in
tobacco control, and will provide an evidence-based, prac-
tical and customizable ROI tool to actual decision-makers.
The ﬁndings are expected to promote and disseminate the
ROI methods and results to foster evidence-driven
decision-making on comprehensive tobacco control in
Europe. By adopting a core methodological design but facil-
itating the incorporation of jurisdiction-speciﬁc analytical
features and data, EQUIPTMOD will be adjustable to ﬁt
the speciﬁc decision problem for multiple users.
There are limitations to the approach we have adopted.
A major component of the model framework is the use of
an underlying quit rate. The underlying quit rate has been
estimated over time as the decrease in the percentage of the
population who are smokers. This estimate has been con-
sistent, and represents the impact of both quitting and re-
lapsing. Similar data on the individual components are
not readily available. As the model works at a population-
level, the use of an underlying quit rate is argued to be a
reasonable compromise.
Analysis is based on a health-care system perspective.
Therefore, costs of social care associated with the diseases
modelled are excluded. While this may be appropriate for
economic evaluation, given the relevant guidelines, further
analysis including social care costs could be conducted
within a scenario analysis.
Within health economics, there is debate over the rele-
vance of including health-care costs that are unrelated to
the speciﬁc context of interest but occur due to an inter-
vention’s impact in extending life. Guidelines typically sug-
gest exclusion of such costs, but allow consideration of
unrelated cost within scenario analysis. In the context of
smoking cessation, such unrelated costs would occur only
in the future. Furthermore, it would only include health-
care costs exclusive of heart disease, stroke, COPD and lung
cancer, whichwould be bothmuch smaller than all health-
care costs and difﬁcult to measure. A further point is that
annual health-care costs for an individual are typically
highest in the year prior to death. By delaying death
through smoking cessation such high health-care costs
are not avoided, but are merely postponed to a later date.
While inclusion of unrelated costs might increase the costs
of quitters versus non-quitters due to their longer life
expectancy, the impact when assessing the cost-
effectiveness of smoking cessation-related interventions
compared to other uses of health-care resources will be
minimal. Inclusion of unrelated costs would lead to the
incremental cost per QALY gained for all treatments which
extend life to be increased by a similar factor—the annual
costs of treating unrelated diseases. If the threshold value
of a QALY is representative of the marginal costs of produc-
ing an additional QALY exclusive of unrelated costs, then
inclusion of unrelated costs would simply lead to an
increase in the appropriate threshold. Therefore, inclusion
of unrelated costs is likely to have a minimal impact on
decisions related to cost-effectiveness. Given both this and
the guidance on costing such studies, we did not include
unrelated health or social care costs.
The development of EQUIPTMOD has several strengths.
The decisions relating tomodel design and data assessment
were made with all constituent partners having an equal
voice with decisions based on consensus. The ‘inverted
cone’ approach to the overall EQUIPT study has led to the
development of a model which meets the speciﬁc needs
for the initial study partners, but has the ﬂexibility to meet
the further needs of additional partners [6]. Intensive
stakeholder engagement throughout the research process
highlights the design to be highly relevant to end-users of
research ﬁndings.
EQUIPTMOD has some limitations. Country-speciﬁc
modelling requires that data are available for each constit-
uent country. However, extensive work within the EQUIPT
transferability framework has allowed identiﬁcation of
those key data parameters for which country-speciﬁc data
are essential, allowing countries with fewer resources to
target the acquisition of the most pertinent data elements.
The initial results highlighted in this paper indicate the
large potential beneﬁts from smoking cessation both at in-
dividual and population levels. Previous studies have
highlighted that interventions designed to assist smoking
cessation are consistently cost-effective (e.g. [61–64]).
EQUIPTMOD will be a further tool available to decision-
makers to assess the cost-effectiveness of such interven-
tions. However, given the multi-faceted approach
necessary to promote smoking cessation, EQUIPTMOD’s
greater application will be as the engine for the EQUIPT
ROI tool to facilitate assessment by policymakers of the
desirability of alternative packages of smoking cessation
interventions.
Given the substantive role possible with the EQUIPT
ROI tool and the potential applications of the underlying
EQUIPTMOD economic model, it is hoped that the model
described in this paperwill be used frequently to assess both
the cost-effectiveness of individual interventions and to
more generally foster evidence-driven decision-making on
comprehensive tobacco control in Europe and beyond.
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